HB0017

Evidence outlook · registrational

Psoriasis: registrational readout pending

Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.

NCT05531682: The study was randomized and quadruple-blind, included a placebo control, and enrolled 160 participants; its primary endpoints were PASI 90 and sPGA 0/1 responses at week 12, which are clinical psoriasis outcomes. Because the registry does not report whether either primary comparison favored HB0017, the evidence is currently limited to the trial design rather than a demonstrated treatment effect.

Conference-abstract-only source (BJD 2024). The abstract reports the 300 mg vs placebo comparison (n=81); the registry lists 160 enrolled across dosing regimens.